| Drug ID: | Drug67 |
|---|---|
| Drug Name: | 2'-Fucosyllactose |
| CID: | 170484 |
| DrugBank ID: | DB16052 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT03847467 |
| Molecular Formula: | C18H32O15 |
| Molecular Weight: | 488.4 g/mol |
| Isomeric SMILES: | C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)O)O)O)O)O |
| Synonyms: | 2'-Fucosyllactose; 41263-94-9; 2'-O-fucosyllactose; Lactose, 2'-o-fucosyl-; 2'-o-l-fucosyl-d-lactose; XO2533XO8R; UNII-XO2533XO8R; DTXSID40194179; D-Glucose, O-6-deoxy-alpha-L-galactopyranosyl-(1-2)-O-beta-D-galactopyranosyl-(1-4)-; (2R,3R,4R,5R)-4-{[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2,3,5,6-tetrahydroxyhexanal |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03847467 | Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy | PHASE1|PHASE2 | RECRUITING | Children's Hospital Medical Center, Cincinnati | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | DRUG: 2'-Fucosyllactose|OTHER: Placebo | Details |
| NCT06050811 | Prebiotics in Reducing Inflammation and Clinical Endpoints in Ulcerative Colitis (PRInCE-UC) | None | RECRUITING | Royal Berkshire NHS Foundation Trust | Ulcerative Colitis | DIETARY_SUPPLEMENT: 2'-Fucosyllactose|DIETARY_SUP… | Details |
| NCT00403923 | Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative Colitis | None | COMPLETED | University Hospitals, Leicester | Lactose Intolerance|Ulcerative Colitis | DIETARY_SUPPLEMENT: Lactose in water | Details |
| NCT06541938 | A Feasibility Study to Use a Handheld, In-Home Breath Test Device to Measure H2 and CH4 Production from Carbohydrate Fermentation and Its Correlation with Persistent Symptoms in Inflammatory Bowel Disease Patients in Remission | Not Available | Recruiting | McMaster University | Inflammatory Bowel Diseases | Dietary Supplement: Fructose Sachet;Dietary Suppl… | Details |
| CTRI/2024/01/061649 | Prevalence and impact of sarcopenia and frailty in inflammatory bowel disease, and the effect of multi-modal interventions on sarcopenia and clinical outcomes in patients with inflammatory bowel disease - NIL | PHASE3 | Not Recruiting | All India Institute of Medical Sciences | Health Condition 1: K509- Crohns disease, unspeci… | Intervention1: High protein anti-inflammatory die… | Details |
| IRCT20170202032367N8 | Investigating the effect of modified specific carbohydrate diet on disease severity, fecal calprotectin level and disability caused by the disease in people with ulcerative colitis. | Not Available | Not Recruiting | Tehran University of Medical Sciences | Inflammatory bowel disease (ulcerative colitis). … | Intervention 1: Intervention group:People in the … | Details |
| NCT05687474 | Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect | Not Available | Recruiting | Centre Hospitalier Universitaire de Liege | Congenital Adrenal Hyperplasia;Familial Hyperinsu… | None | Details |
| IRCT20150304021342N2 | The effects of dietary modification programme (low-fat, low-carb and high-protein diet) on mood status, fatigue and quality of life in patients with ulcerative colitis | Not Available | Not Recruiting | Esfahan University of Medical Sciences | Ulcerative colitis. Ulcerative colitis | Intervention 1: Intervention group: Patients who … | Details |
| KCT0008022 | The effect of preconception care program for women with inflammatory bowel disease: a mixed method study | Not Available | Not Recruiting | University of Ulsan | ;Diseases of the digestive system | Behavioral, Others(Education) : The experimental … | Details |
| NL-OMON49003 | A randomised controlled trial comparing FMT (fecal microbiota transplantation) after budesonide or placebo in patients with active ulcerative colitis: ;Acronym: the FECBUD trial __ - FMT for ulcerative colitis after initiation of budesonide | Not Available | Not Recruiting | Leids Universitair Medisch Centrum | inflammatory bowel disease ulcerative colitis;10… | Intervention Patients with active ulcerative coli… | Details |
| NL-OMON44482 | A randomised controlled trial comparing FECal Microbiota Transplantation after BUDesonide or placebo induction in patients with ulcerative colitis; the FECBUD trial__ - FMT for ulcerative colitis after initiation of budesonide | Not Available | None | Haaglanden Medisch Centrum | inflammatory bowel disease ulcerative colitis;10… | Intervention Patients with active ulcerative coli… | Details |
| CTRI/2017/10/010160 | Evaluation of a Peri-Operative Low Dose Steroid Regimen for Steroid Treated Inflammatory Bowel Disease patients A Prospective Randomised Study | PHASE2|PHASE3 | Recruiting | AIIMS | Health Condition 1: null- patient having infalmma… | Intervention1: Low dose Steroid (LDS) Regimen: Pa… | Details |
| NCT03863886 | Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis | None | UNKNOWN | Carilion Clinic | Crohn Disease|Ulcerative Colitis | PROCEDURE: Endoscopic ultrasound catheter (UM-2R/… | Details |
| NCT00820365 | SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease | PHASE2 | COMPLETED | 4SC AG | Inflammatory Bowel Disease (IBD) | DRUG: SC12267 (4SC-101) | Details |
| NCT05575505 | Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis. | PHASE2 | RECRUITING | Tanta University | Inflammatory Bowel Diseases | DRUG: Pentoxifylline 400 MG | Details |
| NCT06651281 | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) | PHASE3 | RECRUITING | Merck Sharp & Dohme LLC | Crohn Disease|Colitis, Ulcerative | DRUG: Tulisokibart|DRUG: Placebo to tulisokibart | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT04478825 | Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis | PHASE1 | TERMINATED | Bridge Biotherapeutics, Inc. | Ulcerative Colitis | DRUG: BBT-401-1S | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT02447302 | Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis | PHASE2 | COMPLETED | Arena Pharmaceuticals | Ulcerative Colitis | DRUG: Etrasimod|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
2'-Fucosyllactose Modulates the Intestinal Immune Response to Gut Microbiota an…
PMID: 40501496
Year: 2025
Relationship Type:
Mechanism
Score: 9.5
Inflammatory bowel disease (IBD), a recurrent gastrointestinal disease, is characterized by dysbiosis and inflammation. 2'-fucosyllactose (2'-FL) sho…
2'-Fucosyllactose restores the intestinal mucosal barrier in ulcerative colitis…
PMID: 38150914
Year: 2024
Relationship Type:
Mechanism
Score: 9.5
BACKGROUND & AIMS: 2'-Fucosyllactose (2'-FL), the primary constituent of human milk oligosaccharides, has been identified as a potential regulator of…
2'-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier…
PMID: 37111064
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the inte…
2'-Fucosyllactose Ameliorates Inflammatory Bowel Disease by Modulating Gut Micr…
PMID: 35252301
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Gut microbiota dysbiosis, together with goblet cells dysfunction has been observed in ulcerative colitis cases. This study aims to evaluate the poten…
2'-Fucosyllactose Promotes Colonization of Akkermansia muciniphila and Prevents…
PMID: 38393978
Year: 2024
Relationship Type:
Association
Score: 6.5
Impact of 2'-Fucosyllactose on Gut Microbiota Composition in Adults with Chroni…
PMID: 33799455
Year: 2021
Relationship Type:
Clinical Trial
Score: 6.5